This Month in Genetics  by Garber, Kathryn B.
EDITORS’ CORNER
This Month in Genetics
Kathryn B. Garber1,*Pharmacogenetic Help for Outliers
In the United States alone, tens of millions of prescriptions
for the anticoagulant warfarin are written each year, and it
is among the top ten drugs in terms of the number of asso-
ciated serious adverse events. One of the problems with
warfarin is that the appropriate dose can vary by a factor
of ten among patients, so achieving the optimal dose for
an individual takes time and careful monitoring. Genetic
variation inﬂuences the variability in dosage requirements,
and pharmacogenetic information is even included on the
warfarin product label, but large trials demonstrating that
a pharmacogenetic approach predicts warfarin dosage
requirements better than other algorithms has been lack-
ing. The InternationalWarfarin Pharmacogenetics Consor-
tium used a large retrospective analysis that included more
than 5000 patients on warfarin therapy to develop a phar-
macogenetic algorithm that uses genotype information at
CYP2C9 and VKORC1. For the 54% of people that needed
an intermediate warfarin dose, the pharmacogenetic algo-
rithm did no better than a ﬁxed-dose approach at dose
prediction. This makes sense given that the ﬁxed dose
was derived from the appropriate therapeutic dose in an
average group of patients. Where the pharmacogenetic
algorithm did excel was in the tails of the dose distribution;
it signiﬁcantly improved dose prediction in the groups
of patients requiring a high or low dose of warfarin,
compared to a clinical algorithm that didn’t incorporate
genetic information. The next step in this story will be to
determine in a large prospective study whether use of phar-
macogenetic information improves clinical end points,
including the number of adverse events associated with
warfarin therapy.
The International Warfarin Pharmacogenetics Consortium
(2009). N. Engl. J. Med. 360, 753–764. 10.1056/NEJ-
Moa0809329.
Major Role for Copy Number Variation
in Governing Variability in Gene Expression
It makes sense that the more copies of a genetic sequence
you have, the more it might be expressed, but this hypoth-
esis has not been thoroughly tested on a global scale. Two
recent papers in Nature Genetics explored this idea in mice
and found that there is some truth to this idea, but that therelationship of copy number variants (CNVs) to gene
expression is more complicated than this. Both papers
usemultiplemouse strains in attempts to generate compre-
hensive CNV maps. They then try to correlate the CNVs
with tissue-speciﬁc gene expression data. In these studies,
CNVs contribute to a large proportion of the strain-depen-
dent variation in gene expression, but this doesn’t just
include the genes that are encompassed by the CNVs, it
can include expression of genes that are up to 450 kb
away from the CNV breakpoints. In fact, Cahan et al.
found that the vast majority of quantitative trait loci for
gene expression differences mapped outside of the corre-
sponding CNVs. Henrichsen et al. also found that genes
in CNVs tend to be expressed in fewer tissues and to a lower
extent than genes that do not vary in terms of copy
number. CNVs thus seem to make a substantial contribu-
tion to variation in gene expression in mice, both in
expected and in unexpected ways.
Cahan et al. (2009). Nat. Genet. Published online March 8,
2009. 10.1038/ng.350; Henrichsen et al. (2009). Nat. Genet.
Published online March 8, 2009. 10.1038/ng.345.
Rare Alleles Protect against Diabetes
Much of the research into genetic susceptibilities for
complex traits has been based on the idea that common
variation will govern susceptibility to common disease.
Once you ﬁnd an association, though, linkage disequilib-
rium can make it difﬁcult to tease out exactly what the
causal variation is. An alternative approach uses the idea
that the effects of many rare variants together could also
underlie common disease. The problem with ﬁnding these
rare variants is that it generally takes large resequencing
efforts that have only recently become feasible. Nejentsev
et al. worked at the nexus of these approaches to ﬁnd genes
that play a role in Type 1 Diabetes (T1D). Starting mostly
with candidate genes that contain common T1D-associ-
ated polymorphisms, they resequenced to look for rare
variation contributing to T1D. They found four rare vari-
ants, all in IFIH1, that independently lower risk of T1D.
Each of these SNPs either truncates the protein, alters
a conserved splice site, or changes a conserved amino
acid, suggesting that reducing the function of the IFIH1
protein is protective against T1D. Although a common
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resides in a block of linkage disequilibrium that encom-
passes three other genes, making it unclear which was rele-
vant. While highlighting IFIH1 as a gene involved in T1D,
this research also illustrates that studies of rare variation
can be meaningful for common diseases.
Nejentsev et al. (2009). Science. Published online March 5,
2009. 10.1126/science.1167728.
Mouse Model of a Couch Potato
Variation in FTO confers risk of obesity and it appears to do
this through overeating—people with the obesity risk
allele in FTO tend to eat more and to prefer higher fat foods
than do people without the risk allele. How a protein that
demethylates nucleic acids inﬂuences how much we want
to eat is something we don’t understand. To get a better
handle on the physiological role of this protein, Fischer
et al. generated Fto-deﬁcient mice. As early as 2 days after
birth, the Fto/mice start to lag behind their counterparts
in terms of body weight, and they go on to have shorter
body length and less fat mass than do their wild-type
siblings. In contrast to human studies that suggest that
FTO inﬂuences food intake without inﬂuencing energy
expenditure, Fto/ mice seem to be lean because they
burn more energy, not because they eat less. You would
think this means that the mice are overactive, but, in
fact, this extra energy expenditure is seen despite the fact
that Fto/ mice are less active than their wild-type sibs.
Eating fatty food while losing weight without having to
exercise? Sounds like a drug company’s fantasy to me.
Fischer et al. (2009). Nature. Published online February 22,
2009. 10.1038/nature07848.428 The American Journal of Human Genetics 84, 427–428, April 10Role for Neutrophils in Cystic Fibrosis-Associated
Lung Disease
Clearly, mutations in CFTR are necessary and sufﬁcient to
cause cystic ﬁbrosis (CF). But why do some people have
very severe lung disease, whereas others are more mildly
affected? Even if one controls for CFTR mutation, there is
signiﬁcant heritable variation in the severity of lung
disease. To pin down what these modiﬁers might be, Gu
et al. did a case-control association study with a sample
in which everybody had CF because of a homozygous
DF508 CFTR genotype. Their ‘‘cases’’ had severe lung
disease and were compared to ‘‘controls’’ with milder
lung disease. Their results place neutrophil function
central to the variability in lung disease in CF. The gene
they pulled out of their study, IFRD1, encodes a transcrip-
tional coregulator that is upregulated during terminal
differentiation of neutrophils. In people without CF, poly-
morphisms in this gene are associated with variation in
effector function of neutrophils. And in mice, neutrophils
deﬁcient for IFRD1 are signiﬁcantly impaired in effector
function, and—relevant to the association with CF lung
disease—these mice clear Pseudomonas aeruginosa more
slowly than do their wild-type counterparts and in the
context of less inﬂammation. Although signiﬁcant
improvements in management of CF have been achieved
over the past several years, declines in pulmonary function
remain a big challenge and the main cause of death for CF
patients. The association of CF lung disease with IFRD1
suggests that neutrophil function might be a potential
therapeutic target for CF.
Gu et al. (2009). Nature. Published online February 25,
2009. 10.1038/nature17811., 2009
